Literature DB >> 21186272

Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy.

Katrien Lemmens1, Kris Doggen, Gilles W De Keulenaer.   

Abstract

The neuregulin-1 (NRG1)/ErbB system has emerged as a paracrine endothelium-controlled system in the heart, which preserves left ventricular (LV) performance in pathophysiological conditions. Here, we analyze the activity and function of this system in pregnancy, which imparts a physiological condition of LV hemodynamic overload. NRG1 expression and ErbB receptor activation were studied by Western blot analyses in rats and mice at different stages of pregnancy. LV performance was evaluated by transthoracic echocardiography, and myocardial performance was assessed from twitches of isolated papillary muscles. NRG1/ErbB signaling was inhibited by oral treatment of animals with the dual ErbB1/ErbB2 tyrosine kinase inhibitor lapatinib. Analyses of LV tissue revealed that protein expression of different NRG1 isoforms and levels of phosphorylated ErbB2 and ErbB4 significantly increased after 1-2 wk of pregnancy. Lapatinib prevented phosphorylation of ErbB2 and ERK1/2, but not of ErbB4 and protein kinase B (Akt), revealing that lapatinib only partially inhibited NRG1/ErbB signaling in the LV. Lapatinib did not prevent pregnancy-induced changes in LV mass and did not cause apoptotic cell death or fibrosis in the LV. Nevertheless, lapatinib led to premature maternal death of ∼25% during pregnancy and it accentuated pregnancy-induced LV dilatation, significantly reduced LV fractional shortening, and induced abnormalities of twitch relaxation (but not twitch amplitude) of isolated papillary muscles. This is the first study showing that the NRG1/ErbB system is activated, and plays a modulatory role, during physiological hemodynamic overload associated with pregnancy. Inhibiting this system during physiological overload may cause LV dysfunction in the absence of myocardial cell death.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21186272     DOI: 10.1152/ajpheart.00385.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  33 in total

1.  The growth factor receptor ERBB2 regulates mitochondrial activity on a signaling time scale.

Authors:  Nirav Patel; Antoni Barrientos; Ralf Landgraf
Journal:  J Biol Chem       Date:  2013-10-18       Impact factor: 5.157

Review 2.  Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines.

Authors:  Cecilia Vasti; Cecilia M Hertig
Journal:  World J Cardiol       Date:  2014-07-26

Review 3.  Signalling between microvascular endothelium and cardiomyocytes through neuregulin.

Authors:  Emily M Parodi; Bernhard Kuhn
Journal:  Cardiovasc Res       Date:  2014-01-29       Impact factor: 10.787

Review 4.  Pregnancy as a cardiac stress model.

Authors:  Eunhee Chung; Leslie A Leinwand
Journal:  Cardiovasc Res       Date:  2014-01-20       Impact factor: 10.787

5.  Akt and MAPK signaling mediate pregnancy-induced cardiac adaptation.

Authors:  Eunhee Chung; Fan Yeung; Leslie A Leinwand
Journal:  J Appl Physiol (1985)       Date:  2012-02-16

6.  New frontiers in heart hypertrophy during pregnancy.

Authors:  Jingyuan Li; Soban Umar; Marjan Amjedi; Andrea Iorga; Salil Sharma; Rangarajan D Nadadur; Vera Regitz-Zagrosek; Mansoureh Eghbali
Journal:  Am J Cardiovasc Dis       Date:  2012-07-25

7.  MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.

Authors:  Julie Halkein; Sebastien P Tabruyn; Melanie Ricke-Hoch; Arash Haghikia; Ngoc-Quynh-Nhu Nguyen; Michaela Scherr; Karolien Castermans; Ludovic Malvaux; Vincent Lambert; Marc Thiry; Karen Sliwa; Agnes Noel; Joseph A Martial; Denise Hilfiker-Kleiner; Ingrid Struman
Journal:  J Clin Invest       Date:  2013-04-24       Impact factor: 14.808

Review 8.  Neuregulin as a heart failure therapy and mediator of reverse remodeling.

Authors:  Cristi L Galindo; Sergey Ryzhov; Douglas B Sawyer
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 9.  Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.

Authors:  Michel G Khouri; Pamela S Douglas; John R Mackey; Miguel Martin; Jessica M Scott; Marielle Scherrer-Crosbie; Lee W Jones
Journal:  Circulation       Date:  2012-12-04       Impact factor: 29.690

10.  Pregnancy-induced physiological hypertrophy protects against cardiac ischemia-reperfusion injury.

Authors:  Junjie Xiao; Jin Li; Tianzao Xu; Dongcao Lv; Bo Shen; Yang Song; Jiahong Xu
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.